SRPT vs IONS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRPT Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, SRPT trades at 10.8x Forward P/E with -0.4% operating margin (-4.5% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRPT Revenue | IONS Revenue | SRPT Op. Margin | IONS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $300M | $600M | -114.1% | -10.2% | IONS |
| FY2019 | $380M | $1.12B | -185.3% | 32.6% | IONS |
| FY2020 | $460M | $730M | -123.8% | -23.6% | IONS |
| FY2021 | $610M | $810M | -75.1% | -3.7% | IONS |
| FY2022 | $840M | $590M | -63.5% | -69.8% | SRPT |
| FY2023 | $1.14B | $790M | -23.4% | -44.9% | SRPT |
| FY2024 | $1.79B | $710M | 12.2% | -67.4% | SRPT |
| FY2025 | $1.86B | $940M | -37.5% | -40.4% | SRPT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRPT | IONS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $4.7B | Larger Scale | IONS |
| Trailing P/E Ratio Valuation | N/M | 90.9x | Lower Multiple | IONS |
| Forward P/E Ratio Valuation | 10.8x | 90.9x | Lower Multiple | SRPT |
| Revenue Growth (YoY) Growth | -4.5% | +54.9% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | -0.4% | -58.8% | Higher Margin | SRPT |
| Net Profit Margin Profitability | -5.9% | -56.9% | Higher Margin | SRPT |
| Return on Equity (ROE) Capital Efficiency | -8.1% | -108.0% | Higher ROE | SRPT |
| 52-Week Range Position Momentum | 5% ($15โ$25) | 2% ($27โ$87) | Stronger Trend | SRPT |
| Beta / 30D Volatility Risk Regime | 1.47ฮฒ ยท 58% Vol | 0.18ฮฒ ยท 86% Vol | Lower Realized Risk | SRPT |
| Unified Institutional Score Composite Signal | 37.8 / 100 (SELL) | 63.9 / 100 (BUY) | Higher Composite | IONS |